154 related articles for article (PubMed ID: 24291971)
1. [Proposal for rituximab treatment in patients with myasthenia gravis].
Konno S
Rinsho Shinkeigaku; 2013; 53(11):1312-4. PubMed ID: 24291971
[TBL] [Abstract][Full Text] [Related]
2. Use and monitoring of low dose rituximab in myasthenia gravis.
Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
[TBL] [Abstract][Full Text] [Related]
3. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
Pescovitz MD
Am J Transplant; 2006 May; 6(5 Pt 1):859-66. PubMed ID: 16611321
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function.
Marino M; Bartoccioni E; Alboini PE; Evoli A
Ann N Y Acad Sci; 2018 Feb; 1413(1):41-48. PubMed ID: 29369382
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
Iorio R; Damato V; Alboini PE; Evoli A
J Neurol; 2015 May; 262(5):1115-9. PubMed ID: 25308632
[TBL] [Abstract][Full Text] [Related]
6. [A case of refractory generalized myasthenia gravis with anti-acetylcholine receptor antibodies treated with rituximab].
Hayashi R; Tahara M; Oeda T; Konishi T; Sawada H
Rinsho Shinkeigaku; 2015; 55(4):227-32. PubMed ID: 25904250
[TBL] [Abstract][Full Text] [Related]
7. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis.
Burusnukul P; Brennan TD; Cupler EJ
J Clin Neuromuscul Dis; 2010 Dec; 12(2):85-7. PubMed ID: 21386776
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
Li T; Zhang GQ; Li Y; Dong SA; Wang N; Yi M; Qi Y; Zhai H; Yang L; Shi FD; Yang CS
J Clin Neurosci; 2021 Mar; 85():6-12. PubMed ID: 33581791
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for severe myasthenia gravis--experience from five patients.
Lindberg C; Bokarewa M
Acta Neurol Scand; 2010 Oct; 122(4):225-8. PubMed ID: 20199513
[TBL] [Abstract][Full Text] [Related]
10. [Rituximab in treatment for neuroimmunological diseases].
Schröder A; Ellrichmann G; Chehab G; Schneider M; Linker RA; Gold R
Nervenarzt; 2009 Feb; 80(2):155-6, 158-60, 162-5. PubMed ID: 19183926
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for myasthenia gravis: three case reports and review of the literature.
Stieglbauer K; Topakian R; Schäffer V; Aichner FT
J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
[TBL] [Abstract][Full Text] [Related]
13. Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.
Yi JS; Decroos EC; Sanders DB; Weinhold KJ; Guptill JT
Muscle Nerve; 2013 Dec; 48(6):992-3. PubMed ID: 24006142
[No Abstract] [Full Text] [Related]
14. 10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential.
Stieglbauer K; Pichler R; Topakian R
J Neurol Sci; 2017 Apr; 375():241-244. PubMed ID: 28320139
[TBL] [Abstract][Full Text] [Related]
15. Memory B cell resurgence requires repeated rituximab in myasthenia gravis.
Muto K; Matsui N; Unai Y; Sakai W; Haji S; Udaka K; Miki H; Furukawa T; Abe M; Kaji R
Neuromuscul Disord; 2017 Oct; 27(10):918-922. PubMed ID: 28694074
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
Landon-Cardinal O; Friedman D; Guiguet M; Laforêt P; Heming N; Salort-Campana E; Jouen F; Allenbach Y; Boyer O; Chatenoud L; Eymard B; Sharshar T; Benveniste O
J Neuromuscul Dis; 2018; 5(2):241-249. PubMed ID: 29865089
[TBL] [Abstract][Full Text] [Related]
18. Rituximab treatment of myasthenia gravis: A systematic review.
Tandan R; Hehir MK; Waheed W; Howard DB
Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
[TBL] [Abstract][Full Text] [Related]
19. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.
Nelson RP; Pascuzzi RM; Kessler K; Walsh LE; Faught PP; Ramanuja S; Pescovitz MD; Loehrer PJ
J Clin Neuromuscul Dis; 2009 Jun; 10(4):170-7. PubMed ID: 19494727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
